Several studies indicate that aberrant expression of specific β-tubulin isoforms and MAPs strongly correlates with resistance to microtubule targeting agents in various cancers including breast, ovarian, lung and prostate cancers [13, 18]. This evidence concerns the gene C3orf62 and cancer.